At the operating level, EBITDA jumped 39% to ₹367.6 crore in the April-June quarter over ₹264.5 crore last year. The EBITDA expanded significantly to 24.4% versus 19% year-on-year. Shares of Gland Pharma Ltd ended at ₹1,964.45, down by ₹16.60 or 0.84%, on the BSE today (August 5).
